Abstract

Background/aim: this editorial is aimed at providing some insights on cell therapy in patients with diabetic foot ulcers and no-option critical limb-threatening ischemia (CLTI). Methods and results: the present paper revised the available evidence on cell therapy in patients affected by diabetes and peripheral artery disease and reported the main results of a recently published uncontrolled study on the effects of peripheral blood mononuclear cells (PBMNC) therapy in patients with diabetic foot ulcers, no-option CLTI, and small artery disease. All patients included in that study were allocated in a surgery waiting-list for major amputations. Patients treated with autologous PBMNC experienced a significant reduction of pain levels, an increase of oxygen tissue levels, a high rate of healing without the need of a major amputation. Conclusions: the present paper illustrates the possible favorable effects of PBMNC cell therapy in patients with diabetes and peripheral artery disease even in presence of microangiopathy.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call